IQVIA Holdings Inc. $IQV Shares Purchased by WASHINGTON TRUST Co

WASHINGTON TRUST Co grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.6% in the third quarter, Holdings Channel reports. The institutional investor owned 90,286 shares of the medical research company’s stock after acquiring an additional 2,308 shares during the period. WASHINGTON TRUST Co’s holdings in IQVIA were worth $24,273,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. BlackRock Inc. acquired a new stake in shares of IQVIA in the 2nd quarter worth about $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after acquiring an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in IQVIA by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock valued at $282,657,000 after purchasing an additional 66,643 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in IQVIA during the 2nd quarter valued at about $240,911,000. Finally, Bank of America Corp DE acquired a new position in IQVIA during the 2nd quarter valued at about $235,551,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of IQV stock traded up $1.15 during trading on Friday, hitting $279.47. The company’s stock had a trading volume of 981,209 shares, compared to its average volume of 1,322,001. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market cap of $46.00 billion, a PE ratio of 34.67, a P/E/G ratio of 2.45 and a beta of 1.17. The business has a fifty day moving average of $263.98 and a 200-day moving average of $216.43. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $282.98.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period last year, the company posted $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 11.54 earnings per share for the current year.

Insider Activity

In other news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. The trade was a 19.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Stifel Nicolaus increased their price objective on IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. JPMorgan Chase & Co. lifted their target price on IQVIA from $285.00 to $295.00 in a research report on Wednesday, October 14th. Barclays lifted their target price on IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Finally, BMO Capital Markets increased their target price on shares of IQVIA from $270.00 to $305.00 in a report on Monday, October 19th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $278.75.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.